PON1 and chronic myelogenous leukemia, BCR-ABL1 positive: On the other hand, co-treatment of CIGB-258 at 20 μM and 40 μM resulted in a 2.5-fold (p < 0.01) and 2.7-fold (p < 0.01) higher PON activity, respectively, than CML treated HDL3.